Compare Sanofi SA (SNY) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TKO Group Holdings Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while TKO Group Holdings Inc trades at $181.83 (market cap $13.70B). The key difference: Sanofi SA is far larger — about 7.7× TKO Group Holdings Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | TKO | |
|---|---|---|
Market Cap | $104.83B | $13.70B |
Sector | Health | Technology |
52-Week High | $52.34 | $224.96 |
52-Week Low | $41.33 | $155.61 |
Enterprise Value | $121.32B | $17.88B |
Dividend Yield | 5.5% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
TKO trades at $182.79, down 1.26% on the day, with a bearish technical signal from moving averages. The stock shows strong analyst support with 89% buy ratings and a consensus price target of $228.40. Recent financials indicate revenue growth to $5.1B in 2026 with a net income margin of 4.47%, though valuation ratios like a P/E of 67.95 appear elevated. Key developments include a completed $800 million share repurchase and strong UFC event viewership.
The outlook for TKO is positive based on robust analyst consensus and expanding monetization from media deals, but risks include high valuation and recent insider selling. Earnings momentum needs to justify premium multiples, with the next quarterly report on August 3, 2026, critical for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
